Laboratory Medicine ›› 2018, Vol. 33 ›› Issue (7): 637-639.DOI: 10.3969/j.issn.1673-8640.2018.07.014
• Orginal Article • Previous Articles Next Articles
Received:
2017-02-14
Online:
2018-07-30
Published:
2018-07-27
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2018.07.014
分组 | 例数 | Hcy(μmol/L) | R值 | K值 | Angel角 | MA值 | CI值 | 阿司匹林抑制率(%) |
---|---|---|---|---|---|---|---|---|
Hcy升高组 | 60 | 21.35±5.51* | 6.77±1.39 | 1.48±0.48 | 68.63±5.73* | 64.46±4.67* | 0.33±1.60* | 57.18±34.86* |
Hcy正常组 | 60 | 11.18±2.17 | 6.96±1.20 | 1.66±0.63 | 65.51±6.21 | 61.58±4.67 | -0.44±1.45 | 87.80±15.81 |
分组 | 例数 | Hcy(μmol/L) | R值 | K值 | Angel角 | MA值 | CI值 | 阿司匹林抑制率(%) |
---|---|---|---|---|---|---|---|---|
Hcy升高组 | 60 | 21.35±5.51* | 6.77±1.39 | 1.48±0.48 | 68.63±5.73* | 64.46±4.67* | 0.33±1.60* | 57.18±34.86* |
Hcy正常组 | 60 | 11.18±2.17 | 6.96±1.20 | 1.66±0.63 | 65.51±6.21 | 61.58±4.67 | -0.44±1.45 | 87.80±15.81 |
组别 | AS | AR | 合计 |
---|---|---|---|
Hcy升高组 | 35(29.2) | 25(20.8) | 60(50) |
Hcy正常组 | 57(47.5) | 3(2.5) | 60(50) |
合计 | 92(76.7) | 28(23.3) | 120(100) |
组别 | AS | AR | 合计 |
---|---|---|---|
Hcy升高组 | 35(29.2) | 25(20.8) | 60(50) |
Hcy正常组 | 57(47.5) | 3(2.5) | 60(50) |
合计 | 92(76.7) | 28(23.3) | 120(100) |
[1] | 于秀娟,欧超伟,于海华,等. 脑梗塞患者血同型半胱氨酸水平的分析[J]. 中国实验诊断学,2014,18(5):775-777. |
[2] | WALD D S,LAW M,MORRIS J K.Homocysteine and cardiovascular disease:evidence on causality from a meta-analysis[J].BMJ,2002, 325(7374): 1202. |
[3] | 陈德友,刘霖,邹晓,等. 老年心血管病合并高同型半胱氨酸血症患者阿司匹林抵抗发生率及危险因素调查[J]. 中华老年心脑血管病杂志,2015,17(11):1140-1143. |
[4] | 中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国缺血性脑卒中和短暂性脑缺血发作二级预防指南2014[J]. 中华神经科杂志,2015,48(4):258-273. |
[5] | 李渝. 高同型半胱氨酸血症与缺血性脑血管病的相关性分析[J]. 医学综述,2013,19(16):3004-3006. |
[6] | 李晓霞. 血浆同型半胱氨酸水平与脑梗死的关系[J]. 山东医药,2014,54(1):84-86. |
[7] | 喻莉,万安琪,胡明. 同型半胱氨酸与脑梗死的相关性研究[J]. 现代预防医学,2012,39(24):6466-6467. |
[8] | 马聪敏,李亚娟. 高同型半胱氨酸血症研究进展[J].中国实用神经疾病杂志,2008,11(9):132-133. |
[9] | LIM S T, COUGHLAN C A, MURPHY S J, et al.Platelet function testing in transient is chaemic attack and ischaemic stroke:a comprehensive systematic review of the literature[J]. Platelets, 2015, 26(5):402-412. |
[10] | KRASOPOULOS G,BRISTER S J,BEATTIE W S,et al.Aspirin "resistance" and risk of cardiovascular morbidity:aystematic review and meta-analysis[J]. BMJ,2008,336(7637):195-198. |
[11] | 郜晓飞. 阿司匹林抵抗在脑梗死二级预防中与血管事件的关系[J]. 中国现代医生,2014,53(3):34-36. |
[12] | 顾永丽,孙增先. 阿司匹林抵抗与氯吡格雷抵抗的研究进展[J]. 中国医院药学杂志,2016,36(10):866-869. |
[13] | 彭文星,冯频频,石秀锦,等. 阿司匹林抵抗的基因多态性及个体化治疗[J]. 中国药房,2016,27(23):3172-3174. |
[14] | 臧颖卓,史立信,王清涛,等. 急性脑梗死合并高同型半胱氨酸血症患者阿司匹林抵抗及相关因素分析[J]. 脑与神经疾病杂志, 2016,24(12):755-758. |
[15] | 李雪,柯瑟章,陈德友,等. 老年女性冠心病患者阿司匹林抵抗的现患率和危险因素调查[J]. 中华老年心脑血管病杂志,2016,18(10):1034-1037. |
[16] | ZHANG C,CUI T,ZHAO S,et al.The incidence of aspirin resistance and relevant influencing factors in patients on maintenance hemodialysis[J]. Zhonghua Nei Ke Za Zhi,2014,53(3):178-183. |
[1] | FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114. |
[2] | SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120. |
[3] | LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129. |
[4] | YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140. |
[5] | XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146. |
[6] | CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152. |
[7] | . [J]. Laboratory Medicine, 2023, 38(12): 1153-1156. |
[8] | . [J]. Laboratory Medicine, 2023, 38(12): 1157-1159. |
[9] | WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166. |
[10] | YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172. |
[11] | DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176. |
[12] | GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182. |
[13] | . [J]. Laboratory Medicine, 2023, 38(12): 1183-1185. |
[14] | . [J]. Laboratory Medicine, 2023, 38(12): 1186-1190. |
[15] | . [J]. Laboratory Medicine, 2023, 38(12): 1191-1194. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||